Research Analysts’ Weekly Ratings Changes for Vertex Pharmaceuticals (VRTX)

A number of research firms have changed their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):

• 5/6/2026 – Vertex Pharmaceuticals had its “overweight” rating reaffirmed by Barclays PLC. They now have a $615.00 price target on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target raised by Morgan Stanley from $612.00 to $616.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target raised by Royal Bank Of Canada from $541.00 to $543.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target lowered by Sanford C. Bernstein from $577.00 to $572.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Vertex Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $437.00 to $436.00. They now have a “hold” rating on the stock.
• 5/2/2026 – Vertex Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/30/2026 – Vertex Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $441.00 to $437.00. They now have a “hold” rating on the stock.
• 4/27/2026 – Vertex Pharmaceuticals was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/14/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 4/10/2026 – Vertex Pharmaceuticals had its price target raised by Morgan Stanley from $596.00 to $612.00. They now have an “overweight” rating on the stock.
• 3/25/2026 – Vertex Pharmaceuticals was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/18/2026 – Vertex Pharmaceuticals was upgraded by Maxim Group from “hold” to “buy”. They now have a $575.00 price target on the stock.
• 3/11/2026 – Vertex Pharmaceuticals had its price target raised by Truist Financial Corporation from $490.00 to $525.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Morgan Stanley from $570.00 to $596.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Bank of America Corporation from $571.00 to $598.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Citigroup Inc. from $575.00 to $585.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $580.00 price target on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $540.00 to $600.00. They now have an “outperform” rating on the stock.
• 3/10/2026 – Vertex Pharmaceuticals had its price target raised by HC Wainwright from $591.00 to $641.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Duncan Mckechnie sold 4,910 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the completion of the transaction, the executive vice president owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 58,613 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $468.83, for a total value of $27,479,532.79. Following the completion of the transaction, the executive vice president directly owned 58,934 shares of the company’s stock, valued at approximately $27,630,027.22. This trade represents a 49.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 81,853 shares of company stock worth $38,479,135 in the last ninety days. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.